# Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H/dMMR Stage II or III Colorectal Cancer

Source: https://onco.cc/trials/nct05841134/  
OnCo record `nct05841134` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of tislelizumab in colorectal cancer, run by The First Affiliated Hospital of Zhengzhou University, not yet recruiting.

## Summary

Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H/dMMR Stage II or III Colorectal Cancer is a phase 2, interventional study registered as NCT05841134 by The First Affiliated Hospital of Zhengzhou University, with a registry enrolment figure of 25 participants, started 2023-06-01 and due to reach its primary completion in 2024-12-31. Interventions recorded: Tislelizumab. Conditions listed: MSI-H Colorectal Cancer; Tislelizumab; Oxaliplatin; Capecitabine. Primary outcome: Percentage of Participants With Pathological Complete Response (pCR). Colorectal eligibility wording from the registry: "Patients with colon or rectal adenocarcinoma confirmed by histology or cytology;". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT05841134
- Phase: 2
- Setting: Multicenter, Single-arm, Open-label Phase II Clinical Study of Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H/dMMR Stage II or III Colorectal Cancer
- Sponsor: The First Affiliated Hospital of Zhengzhou University
- Enrolled: 25

## Sources

- ClinicalTrials.gov NCT05841134: https://clinicaltrials.gov/study/NCT05841134

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Mismatch-repair deficient (MSI-high) colorectal cancer](https://onco.cc/cancers/msi-high-colorectal/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Tislelizumab](https://onco.cc/drugs/tislelizumab/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05841134.json